No Exception?

Pharmaceutical companies, universities, economists, and others worry that drug and biomedical discoveries will be thwarted by the growing cost of access to patented research tools such as databases, peptides, biomarkers, and bioassays. And a legal avenue long used to circumvent these costs -- the ex...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical Executive Vol. 25; no. 5; p. 66
Main Author Buck, Margaret
Format Trade Publication Article
LanguageEnglish
Published Monmouth Junction MultiMedia Healthcare Inc 01.05.2005
Subjects
Biomedical research
Cell adhesion & migration
Defense
Drugs
FDA approval
Federal court decisions
Peptides
Pharmaceutical industry
R&D
Research & development
Researchers
Solutions
User fees
United States > US
Online AccessGet full text

Cover

More Information
Summary:Pharmaceutical companies, universities, economists, and others worry that drug and biomedical discoveries will be thwarted by the growing cost of access to patented research tools such as databases, peptides, biomarkers, and bioassays. And a legal avenue long used to circumvent these costs -- the experimental use defense -- is no longer an easy fallback. Fortunately, savvy researchers on all sides of the issue have come up with creative ways to work around the limitations of the experimental use defense. In fact, some universities and most of the industry have developed smart, working solutions to the issue of access to patented research tools -- solutions that guarantee that the climate for research will remain robust. Here are a few of these solutions: 1. taking licenses, 2. inventing around patents, 3. going offshore, 4. building and using public databases, 5. court challenges, 6. flying under the radar, and 7. research tool registry.
ISSN:0279-6570
2150-735X